SAMRAT PHARMACHEM
|
SAMRAT PHARMACHEM Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 |
| CEPS(Rs) | 9.09 | 55.91 | 57.54 | 18.86 | 15.09 |
| DPS(Rs) | 1.00 | 1.00 | 1.00 | - | - |
| Book NAV/Share(Rs) | 210.37 | 204.37 | 151.54 | 95.92 | 78.66 |
| Tax Rate(%) | 14.19 | 26.19 | 27.19 | 27.38 | 26.76 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 0.88 | 7.70 | 10.93 | 4.24 | 4.22 |
| EBIT Margin(%) | 1.14 | 7.65 | 10.95 | 4.22 | 4.30 |
| Pre Tax Margin(%) | 0.90 | 7.25 | 10.64 | 3.59 | 3.68 |
| PAT Margin (%) | 0.77 | 5.35 | 7.75 | 2.61 | 2.70 |
| Cash Profit Margin (%) | 1.00 | 5.56 | 8.02 | 2.85 | 2.97 |
| Performance Ratios | |||||
| ROA(%) | 1.81 | 16.53 | 24.20 | 9.22 | 8.60 |
| ROE(%) | 3.38 | 30.25 | 44.95 | 19.77 | 19.10 |
| ROCE(%) | 4.13 | 34.91 | 52.33 | 23.90 | 22.43 |
| Asset Turnover(x) | 2.36 | 3.09 | 3.12 | 3.53 | 3.19 |
| Sales/Fixed Asset(x) | 17.13 | 19.95 | 15.35 | 16.07 | 14.06 |
| Working Capital/Sales(x) | 6.10 | 6.77 | 6.54 | 10.22 | 9.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.06 | 0.05 | 0.07 | 0.06 | 0.07 |
| Receivable days | 78.39 | 55.96 | 63.02 | 54.31 | 56.75 |
| Inventory Days | 34.48 | 26.40 | 19.60 | 26.94 | 31.01 |
| Payable days | 53.71 | 36.30 | 39.45 | 45.34 | 52.01 |
| Valuation Parameters | |||||
| PER(x) | 47.64 | 6.89 | 8.72 | 7.88 | 4.37 |
| PCE(x) | 36.67 | 6.64 | 8.42 | 7.21 | 3.97 |
| Price/Book(x) | 1.59 | 1.82 | 3.20 | 1.42 | 0.76 |
| Yield(%) | 0.30 | 0.27 | 0.21 | - | - |
| EV/Net Sales(x) | 0.36 | 0.39 | 0.64 | 0.27 | 0.19 |
| EV/Core EBITDA(x) | 26.40 | 4.98 | 5.73 | 5.29 | 3.71 |
| EV/EBIT(x) | 31.73 | 5.11 | 5.87 | 5.60 | 3.95 |
| EV/CE(x) | 1.39 | 1.48 | 1.69 | 0.84 | 0.46 |
| M Cap / Sales | 0.37 | 0.37 | 0.68 | 0.23 | 0.13 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -9.36 | 40.09 | 23.87 | 30.24 | 23.68 |
| Core EBITDA Growth(%) | -84.21 | -1.87 | 172.36 | 26.79 | 98.19 |
| EBIT Growth(%) | -86.50 | -2.11 | 181.60 | 27.46 | 110.30 |
| PAT Growth(%) | -87.00 | -3.23 | 222.22 | 25.88 | 175.91 |
| EPS Growth(%) | -87.00 | -3.23 | 222.22 | 25.88 | 175.91 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.13 | 0.30 | 0.16 | 0.30 | 0.39 |
| Current Ratio(x) | 1.82 | 1.86 | 1.91 | 1.73 | 1.47 |
| Quick Ratio(x) | 1.45 | 1.25 | 1.58 | 1.31 | 0.91 |
| Interest Cover(x) | 4.67 | 19.29 | 35.99 | 6.75 | 6.91 |
| Total Debt/Mcap(x) | 0.08 | 0.16 | 0.05 | 0.21 | 0.51 |
Compare Financial Ratios of peers of SAMRAT PHARMACHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SAMRAT PHARMACHEM | ₹106.0 Cr | -11.2% | -18.4% | -17.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,936.0 Cr | -5.8% | -3.2% | 35.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹152,157.0 Cr | -2.8% | -3.6% | 44.7% | Stock Analytics | |
| CIPLA | ₹116,200.0 Cr | -3.9% | -0.5% | 13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹111,325.0 Cr | -1.2% | 7.1% | 17.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,037.4 Cr | -2.7% | -0.1% | 40.9% | Stock Analytics | |
SAMRAT PHARMACHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SAMRAT PHARMACHEM | -11.2% |
-18.4% |
-17.5% |
| SENSEX | -2.1% |
-6.4% |
7% |
You may also like the below Video Courses
